ESCMID Global 2026: Balancing Speed and Quality in Rapid Diagnostics

Overview

Rapid diagnostic technologies are advancing swiftly, offering faster results in infectious disease detection and antimicrobial resistance (AMR) profiling. However, ESCMID Global 2026 highlighted the critical need to balance speed with quality and integration into clinical workflows to truly improve patient outcomes.

Background

The demand for rapid diagnostic tests is increasing, driven by pressures on laboratories to deliver faster results without compromising accuracy. Neonatal sepsis and AMR remain significant diagnostic challenges due to complex sample requirements and the need for timely susceptibility data. Emerging technologies such as nanoplasmonic colorimetry, Raman micro-spectroscopy, and AI-enhanced methods are expanding diagnostic capabilities beyond traditional sequencing. Yet, successful adoption depends on regulatory alignment, digital innovation, and integration within the broader One Health framework.

Data Highlights

Emerging diagnostic technologies discussed include ultra-rapid nanoplasmonic colorimetry, nanomotion-based systems, Raman micro-spectroscopy, AI tools like CarbaDetector, structured illumination microscopy, and expanded MALDI-TOF applications. These aim to reduce time to diagnosis and improve pathogen and AMR detection, including in pediatric settings. Regulatory convergence and digital twins are being explored to support validation and adoption.

Key Findings

• Rapid diagnostics must maintain quality to avoid compromising clinical decision-making despite pressures for faster turnaround times.
• Neonatal sepsis and antimicrobial resistance remain challenging areas requiring sensitive, rapid, and comprehensive testing approaches.
• New technologies such as nanoplasmonic colorimetry, Raman micro-spectroscopy, and AI-integrated platforms show promise for faster, culture-free pathogen identification.
• Integration of diagnostics into clinical workflows and antimicrobial stewardship programs is essential to translate faster results into improved patient outcomes.
• Regulatory convergence and digital innovations like digital twins are emerging to facilitate safe and effective adoption of complex diagnostic tools.
• The One Health perspective underscores the need to consider diagnostics within the interconnected human, animal, and environmental health ecosystem.

Clinical Implications

Clinicians and laboratory professionals should prioritize diagnostic stewardship by ensuring rapid tests are validated and integrated into clinical pathways to support appropriate antimicrobial use and patient management. Adoption of novel technologies requires collaboration across disciplines and alignment with regulatory standards to maximize clinical benefit. Maintaining quality alongside speed is critical to avoid downstream bottlenecks and suboptimal care.

Conclusion

While rapid diagnostic technologies are evolving rapidly, their true value depends on quality assurance, clinical integration, and systemic readiness. ESCMID Global 2026 emphasized that advancing diagnostics must be matched by evolving healthcare systems to improve outcomes effectively.

References

1. ESCMID Global 2026 -- Faster Diagnostics at What Cost?